[THE INVESTOR] Medipost announced on Aug. 10 that it has obtained a US patent for administering mesenchymal stem cells derived from umbilical cord blood to treat nerve injuries.

“This patented method can be applied to treat hypoxic-ischemic brain injury strokes, Alzheimer’s, Pick’s, Huntington’s and Lou Gehrig’s diseases, and traumatic central nervous system disorders,” according to the biotechnology company. 



This is the 13th patent Medipost obtained this year, the highest number among South Korean bio and medicine companies. It owns 65 patents in total, 43 of which are from overseas, and 32 of the patents are related to cranial nerve disorders.

By Hwang You-mee (glamazon@heraldcorp.com)